Clinical Trials
34 trialsHAIC Plus Toripalimab vs. HAIC Plus Sorafenib for HCC With PVTT: a Non-comparative, Prospective, Randomized Trial
Sun Yat-sen University
TACE+Tilelizumab+Sorafenib in the Treatment of BCLC Stage C HCC
First Affiliated Hospital of Zhejiang University
Individualized Induction Therapy for Non-elderly Acute Myeloid Leukemia Patients With Adverse Risk Features
The First Affiliated Hospital of Soochow University
Study of Everolimus and Sorafenib in Patients With Advanced Thyroid Cancer Who Progressed on Sorafenib Alone
Thomas Jefferson University
Evaluate the Efficacy of Sorafenib in Renal Cell Carcinoma Patients After a Radical Resection of the Metastases
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
A Randomized Phase II Trial of Surgery Plus Sorafenib vs. Sorafenib Alone for Hepatocellular Cancer (HCC) With Portal Vein Invasion
White Plains Hospital
Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy
Samsung Medical Center
Phase 2b Study of Taxol Plus Sorafenib or Placebo in Patients With Advanced Breast Cancer
Northwestern University
Phase 2 Study of Sorafenib Plus HAIC of FOLFOX vs. Sorafenib Plus HAIC of OXA for Advanced HCC
Sun Yat-sen University
HAIC of FOLFOX Plus Sorafenib vs HAIC of FOLFIRINOX Plus Sorafenib for Advcanced HCC
Sun Yat-sen University
Molecularly Target Therapy With GEMOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma
Shanghai Jiao Tong University School of Medicine
COTSOM
Asan Medical Center
TACTICS
Kindai University
Efficacy and Safety of Bevacizumab Plus Sorafenib for the Third-line Treatment in Metastatic Renal Cancer Patients
Peking University Cancer Hospital & Institute
Metformin Plus Sorafenib for Advanced HCC
Tianjin Medical University Cancer Institute and Hospital
STREAM
University Hospital, Essen
SoraDox
Martin-Luther-Universität Halle-Wittenberg
Sorafenib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Stage III Melanoma
National Cancer Institute (NCI)
Cisplatin, Gemcitabine Hydrochloride, and Sorafenib Tosylate in Treating Patients With Transitional Cell Cancer of the Bladder
National Cancer Institute (NCI)
Sorafenib Combined With Transarterial Chemoembolization in Treating HBV-infected Patients With Intermediate Hepatocellular Carcinoma
Shandong Cancer Hospital and Institute
Trial of Transcatheter Arterial Chemoembolization (TACE) With Sorafenib for Locally Advanced Hepatocellular Carcinoma (HCC)
Chung-Ang University
Clinical Study of Sorafenib and Zoledronic Acid to Treat Advanced HCC
Fudan University
Sorafenib and FOLFIRI Regimen in 2nd Colorectal Cancer (CRC) After Failure of Oxaliplatin Treatment
Fudan University
Sorafenib Tosylate in Treating Patients With Liver Cancer That Can Be Removed by Surgery
National Cancer Institute (NCI)
AGuo
ChineseAMS
Sorafenib in Treating Patients With Angiosarcoma That is Locally Advanced, Metastatic, or Unable to Be Removed by Surgery
National Cancer Institute (NCI)
Sorafenib and Erlotinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Has Not Responded to Chemotherapy
National Cancer Institute (NCI)
SMS
King's College London
Erlotinib and Sorafenib in Chemonaive Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer
Universitair Ziekenhuis Brussel
PAXO
University of Turin, Italy
HCC
Combined Military Hospital, Pakistan
GCT
Fondation Wygrajmy Zdrowie
MAPS
Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente
SECOX
The University of Hong Kong